Numinus Wellness Inc.(NUMI)
(NUMI)
Kvartalsrapport (Q2)
13 dager siden‧25min
Ordredybde
Stengt
Antall
Kjøp
0
Selg
Antall
0
Siste handler
Tid | Pris | Antall | Kjøpere | Selger |
---|---|---|---|---|
- | - | - | - |
Volumvektet snittpris (VWAP)
-Volumvektet snittpris (VWAP)
-Omsetning (CAD)
2 830Meglerstatistikk
Fant ingen data
Selskapshendelser
Kommende | |
---|---|
Selskapskalender ikke tilgjengelig |
Historisk | ||
---|---|---|
2024 Kvartalsrapport (Q2) | 15. apr. | |
2024 Kvartalsrapport (Q1) | 15. jan. | |
2023 Kvartalsrapport (Q4) | 29. nov. 2023 | |
2023 Kvartalsrapport (Q3) | 17. juli 2023 | |
2023 Kvartalsrapport (Q2) | 13. apr. 2023 |
Data hentes fra Quartr
Nyheter og Analyser
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Kvartalsrapport (Q2)
13 dager siden‧25min
Nyheter og Analyser
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Selskapshendelser
Kommende | |
---|---|
Selskapskalender ikke tilgjengelig |
Historisk | ||
---|---|---|
2024 Kvartalsrapport (Q2) | 15. apr. | |
2024 Kvartalsrapport (Q1) | 15. jan. | |
2023 Kvartalsrapport (Q4) | 29. nov. 2023 | |
2023 Kvartalsrapport (Q3) | 17. juli 2023 | |
2023 Kvartalsrapport (Q2) | 13. apr. 2023 |
Data hentes fra Quartr
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
- 8. nov. 20238. nov. 2023623 registrerte eiere på Nordnet.. imponerende, jeg trodde det bare var jeg som følger sånne sære aksjer😊 er ellers i cmps, cybin og atai. Hva tror dere om numinus fremover?28. nov. 202328. nov. 2023Compass should be releasing phase 2 trial results for psilocybin vs PTSD by the end of the year, and some phase 3 data in summer 2024, so that could be interesting. Atai has data from a study on CIAS treatment using their RL-007 compounds coming in 2H of 2024. I would guess that is a significantly smaller patient demographic and I don't know anything about RL-007, but it's something. Numinus will hold an annual results conference call tomorrow. I don't think they have any new products coming out any time soon, but then again I haven't been following for a long time.
- Numinus Wellness positioned to benefit from multi-billion psychedelic industry ... "Water Tower Research highlighted the recently completed acquisition of Novamind as being transformative for Numinus both strategically and financially establishing its first footprint in the US with eight wellness clinics. Novamind also quintuples Numinus’ run-rate revenue base to around C$16 million, making it one of the largest revenue generators in the psychedelic space and the broker projected that revenues could expand at a compound average growth rate of 116% over the next three years to around C$70mln. Novamind will also improve the group’s gross margins and this will accelerate the path to profitability for Numinus which the broker now expects to be achieved by 2025. Together with the Novamind acquisition the key drivers to profitability according to the broker are revenue acceleration from the expansion of Numinus’ wellness clinic network from the current 13 to 35 by the end of full-year 2025; expansion of higher-margin product offerings which could drive gross margins from the mid-20% range currently to the low 40% range; and operating leverage efficiencies because of scaling up. Buttressed by a strong balance sheet, with more than C$40mln and no debt, Water Tower Research said Numinus is well positioned to continue to expand its clinic network across North America where the regulatory barriers to psychedelics for therapeutic purposes are slowly being dismantled." https://www.proactiveinvestors.co.uk/companies/news/994069/numinus-wellness-positioned-to-benefit-from-multi-billion-psychedelic-industry-analysts-say-994069.html
- Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product https://ca.finance.yahoo.com/news/numinus-submits-clinical-trial-application-130000757.html
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Kvartalsrapport (Q2)
13 dager siden‧25min
Nyheter og Analyser
Nyheter og/eller generelle investeringsanbefalinger, eller utdrag av disse på denne siden og øvrige lenker, er produsert og levert av den spesifiserte leverandøren. Nordnet har ikke deltatt i utarbeidelsen, og har ikke gjennomgått eller gjort endringer i materialet. Les mer om investeringsanbefalinger.
Shareville
Bli med i samtalen på SharevilleEt fellesskap av investorer som deler innsikt og kunnskap i sine porteføljer.
Logg inn
- 8. nov. 20238. nov. 2023623 registrerte eiere på Nordnet.. imponerende, jeg trodde det bare var jeg som følger sånne sære aksjer😊 er ellers i cmps, cybin og atai. Hva tror dere om numinus fremover?28. nov. 202328. nov. 2023Compass should be releasing phase 2 trial results for psilocybin vs PTSD by the end of the year, and some phase 3 data in summer 2024, so that could be interesting. Atai has data from a study on CIAS treatment using their RL-007 compounds coming in 2H of 2024. I would guess that is a significantly smaller patient demographic and I don't know anything about RL-007, but it's something. Numinus will hold an annual results conference call tomorrow. I don't think they have any new products coming out any time soon, but then again I haven't been following for a long time.
- Numinus Wellness positioned to benefit from multi-billion psychedelic industry ... "Water Tower Research highlighted the recently completed acquisition of Novamind as being transformative for Numinus both strategically and financially establishing its first footprint in the US with eight wellness clinics. Novamind also quintuples Numinus’ run-rate revenue base to around C$16 million, making it one of the largest revenue generators in the psychedelic space and the broker projected that revenues could expand at a compound average growth rate of 116% over the next three years to around C$70mln. Novamind will also improve the group’s gross margins and this will accelerate the path to profitability for Numinus which the broker now expects to be achieved by 2025. Together with the Novamind acquisition the key drivers to profitability according to the broker are revenue acceleration from the expansion of Numinus’ wellness clinic network from the current 13 to 35 by the end of full-year 2025; expansion of higher-margin product offerings which could drive gross margins from the mid-20% range currently to the low 40% range; and operating leverage efficiencies because of scaling up. Buttressed by a strong balance sheet, with more than C$40mln and no debt, Water Tower Research said Numinus is well positioned to continue to expand its clinic network across North America where the regulatory barriers to psychedelics for therapeutic purposes are slowly being dismantled." https://www.proactiveinvestors.co.uk/companies/news/994069/numinus-wellness-positioned-to-benefit-from-multi-billion-psychedelic-industry-analysts-say-994069.html
- Numinus Submits Clinical Trial Application for Phase 1 Trial on Proprietary Psilocybin Product https://ca.finance.yahoo.com/news/numinus-submits-clinical-trial-application-130000757.html
Kommentarene ovenfor kommer fra brukere på Nordnets sosiale nettverk Shareville og er verken redigert eller forhåndsvist av Nordnet. De innebærer ikke at Nordnet gir investeringsråd eller investeringsanbefalinger. Nordnet påtar seg ikke ansvar for kommentarene.
Ordredybde
Stengt
Antall
Kjøp
0
Selg
Antall
0
Siste handler
Tid | Pris | Antall | Kjøpere | Selger |
---|---|---|---|---|
- | - | - | - |
Volumvektet snittpris (VWAP)
-Volumvektet snittpris (VWAP)
-Omsetning (CAD)
2 830Meglerstatistikk
Fant ingen data
Selskapshendelser
Kommende | |
---|---|
Selskapskalender ikke tilgjengelig |
Historisk | ||
---|---|---|
2024 Kvartalsrapport (Q2) | 15. apr. | |
2024 Kvartalsrapport (Q1) | 15. jan. | |
2023 Kvartalsrapport (Q4) | 29. nov. 2023 | |
2023 Kvartalsrapport (Q3) | 17. juli 2023 | |
2023 Kvartalsrapport (Q2) | 13. apr. 2023 |
Data hentes fra Quartr